Starpharma Holdings Ltd
ASX:SPL

Watchlist Manager
Starpharma Holdings Ltd Logo
Starpharma Holdings Ltd
ASX:SPL
Watchlist
Price: 0.3575 AUD -2.05% Market Closed
Market Cap: 149.5m AUD

Operating Margin

-170.8%
Current
Improving
by 56.4%
vs 3-y average of -227.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-170.8%
=
Operating Income
AU$-10m
/
Revenue
AU$5.9m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-170.8%
=
Operating Income
AU$-10m
/
Revenue
AU$5.9m

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Starpharma Holdings Ltd
ASX:SPL
149.5m AUD
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
526.1B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.8B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
217.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
221.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.7B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
213.9B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...
No Stocks Found

Market Distribution

Lower than 71% of companies in Australia
Percentile
29th
Based on 2 656 companies
29th percentile
-170.8%
Low
-1 894 850% — -130.1%
Typical Range
-130.1% — 10.8%
High
10.8% — 145 596.9%
Distribution Statistics
Australia
Min -1 894 850%
30th Percentile -130.1%
Median 1.6%
70th Percentile 10.8%
Max 145 596.9%

Starpharma Holdings Ltd
Glance View

Market Cap
149.5m AUD
Industry
Pharmaceuticals

Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The company is headquartered in Melbourne, Victoria and currently employs 50 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The firm has two core development programs: VivaGel portfolio and Dendrimer Enhanced Product (DEP) drug delivery. VivaGel BV for bacterial vaginosis (BV) is a women’s health product. The company is available for sale under the brand names, Betafem BV Gel (UK), Betadine BV (Europe), Betadine BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand). DEP is a drug delivery platform, which provides demonstrated reproducible preclinical benefits across various internal and partnered DEP programs, including improved efficacy, safety, and survival. The firm has three internal DEP products includes DEP docetaxel, DEP cabazitaxel and DEP irinotecan. These internal DEP Products are in clinical development. The firm develops several products internally and others via commercial partnerships.

SPL Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-170.8%
=
Operating Income
AU$-10m
/
Revenue
AU$5.9m
What is Starpharma Holdings Ltd's current Operating Margin?

The current Operating Margin for Starpharma Holdings Ltd is -170.8%, which is above its 3-year median of -227.1%.

How has Operating Margin changed over time?

Over the last 3 years, Starpharma Holdings Ltd’s Operating Margin has increased from -335.1% to -170.8%. During this period, it reached a low of -374.8% on Jun 30, 2023 and a high of -79.3% on Dec 31, 2023.

Back to Top